- Home
- VSTD vs BIAF Comparison
VSTD vs BIAF Comparison
Compare VSTD & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTD | BIAF |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | 259 | 57 |
| Industry | Restaurants | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 4.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VSTD | BIAF |
|---|---|---|
| Price | $0.28 | $1.04 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 76.8K | ★ 226.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.16 |
| 52 Week High | $2.20 | $13.50 |
Technical Indicators
Market Signals| Indicator | VSTD | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 47.36 |
| Support Level | $0.21 | $0.90 |
| Resistance Level | $0.35 | $1.45 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 70.15 | 28.57 |
Price Performance
Historical ComparisonAbout VSTD Vestand Inc.
Vestand Inc is a California-based fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.